Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 28, 2024 653 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR The 10-year cancer plan: is improving cancer survival still a priority... December 8, 2022 On World Cancer Day, ESMO Renews a Longstanding Commitment to Closing... February 3, 2022 Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... September 7, 2022 Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking March 21, 2025 Load more HOT NEWS New lung cancer treatment combo approved on NHS in England Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery... Man Offers Free Lawn Mowing Service To Elderly And Veterans FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular...
